Morgan Stanley Ikena Oncology, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Morgan Stanley holds 27,416 shares of IKNA stock, worth $37,834. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,416

Previous 12,571 118.09%

Holding current value

$37,834

Previous $16,000 125.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$1.03 - $1.47 $15,290 - $21,822	14,845 Added 118.09%	27,416 $36,000
Q1 2025 May 15, 2025	SELL	$1.28 - $1.69 $3,624 - $4,786	-2,832 Reduced 18.39%	12,571 $16,000
Q3 2024 May 14, 2025	SELL	$1.6 - $1.85 $40,753 - $47,121	-25,471 Reduced 62.32%	15,403 $26,000
Q3 2024 Nov 14, 2024	SELL	$1.6 - $1.85 $40,753 - $47,121	-25,471 Reduced 62.32%	15,403 $26,000
Q2 2024 May 14, 2025	BUY	$1.24 - $1.82 $31,584 - $46,357	25,471 Added 165.36%	40,874 $67,000
Q2 2024 Oct 17, 2024	SELL	$1.24 - $1.82 $10,621 - $15,590	-8,566 Reduced 17.33%	40,874 $67,000
Q2 2024 Aug 14, 2024	SELL	$1.24 - $1.82 $10,621 - $15,590	-8,566 Reduced 17.33%	40,874 $67,000
Q1 2024 Oct 17, 2024	BUY	$1.27 - $2.0 $10,878 - $17,132	8,566 Added 20.96%	49,440 $70,000
Q1 2024 Aug 16, 2024	SELL	$1.27 - $2.0 $24,303 - $38,274	-19,137 Reduced 27.91%	49,440 $70,000
Q1 2024 May 15, 2024	SELL	$1.27 - $2.0 $24,303 - $38,274	-19,137 Reduced 27.91%	49,440 $70,000
Q4 2023 Aug 16, 2024	BUY	$1.33 - $4.4 $36,844 - $121,893	27,703 Added 67.78%	68,577 $135,000
Q4 2023 Feb 13, 2024	BUY	$1.33 - $4.4 $70,306 - $232,592	52,862 Added 336.38%	68,577 $135,000
Q3 2023 Nov 15, 2023	BUY	$4.09 - $6.43 $2,977 - $4,681	728 Added 4.86%	15,715 $68,000
Q2 2023 Aug 14, 2023	BUY	$3.5 - $7.31 $5,246 - $10,957	1,499 Added 11.11%	14,987 $98,000
Q1 2023 May 15, 2023	BUY	$2.62 - $4.97 $25,725 - $48,800	9,819 Added 267.62%	13,488 $46,000
Q4 2022 Feb 14, 2023	SELL	$2.0 - $3.7 $95,692 - $177,030	-47,846 Reduced 92.88%	3,669 $9,000
Q3 2022 Nov 14, 2022	SELL	$3.46 - $6.0 $81,628 - $141,552	-23,592 Reduced 31.41%	51,515 $183,000
Q2 2022 Oct 27, 2022	BUY	$3.23 - $7.4 $200,893 - $460,250	62,196 Added 481.73%	75,107 $332,000
Q2 2022 Aug 15, 2022	BUY	$3.23 - $7.4 $200,893 - $460,250	62,196 Added 481.73%	75,107 $332,000
Q1 2022 Oct 27, 2022	SELL	$5.61 - $13.85 $348,919 - $861,414	-62,196 Reduced 82.81%	12,911 $78,000
Q1 2022 May 13, 2022	BUY	$5.61 - $13.85 $4,325 - $10,678	771 Added 6.35%	12,911 $78,000
Q4 2021 Feb 14, 2022	BUY	$10.52 - $16.96 $93,722 - $151,096	8,909 Added 275.74%	12,140 $153,000
Q3 2021 Nov 15, 2021	BUY	$9.82 - $15.23 $31,728 - $49,208	3,231 New	3,231 $41,000

Others Institutions Holding IKNA

# of Institutions

Shares Held

33.6M

Call Options Held

Put Options Held

View Full List

About Ikena Oncology, Inc.

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $50M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

More about IKNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account